Cenicriviroc for non-alcoholic steatohepatitis (NASH)

featured image
Therapeutic Areas: Hepatology
Year: 2017

Cenicriviroc is a new experimental once-daily oral tablet that may improve liver fibrosis in patients with NASH by targeting and blocking the immune and inflammatory pathways responsible for fibrosis. If licensed, cenicriviroc has the potential to establish itself as both a single-agent and as a cornerstone treatment for NASH.